#VisualAbstract: Adjuvant Atezolizumab Does Not Provide Benefit in Early Triple-Negative Breast Cancer
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Tag: triple negative breast cancer
#VisualAbstract: Camrelizumab with Chemotherapy is an Effective Neoadjuvant Therapy in Patients With Triple-Negative Breast Cancer
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Addition of pembrolizumab to chemotherapy improves early-stage triple-negative breast cancer survival
1. In this randomized controlled trial, among patients with early-stage triple-negative breast cancer (TNBC), the addition of neoadjuvant and adjuvant ...
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
1. The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse ...
#VisualAbstract: Pembrolizumab Increases Survival in Early-Stage Triple-Negative Breast Cancer
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Optimizing Subtyping-Based Therapy in Triple-Negative Breast Cancer
1. The median progression-free survival was improved with the pooled subtyping-based therapy group compared to the control group (11.3 months ...
#VisualAbstract: Atezolizumab With Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
1. Progression-free survival was 4.1 months in the combination arm vs 2.2 months in the monotherapy arm with an HR ...
Atezolizumab With Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
1. Progression-free survival was 4.1 months in the combination arm vs 2.2 months in the monotherapy arm with an HR ...
Pembrolizumab and carboplatin plus docetaxel treatment regimens may provide options for patients with triple-negative breast cancer who are ineligible for anthracycline-based regimens
1. Overall pathologic complete response to treatment of triple-negative breast cancer with a non-anthracycline regimen was 58% 2. The estimated ...
Cisplatin with Veliparib in BRCA Stratified Metastatic Triple-Negative Breast Cancer
1. There was some progression-free survival benefit in adding veliparib to cisplatin in patients who had homologous recombination DNA repair ...